A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO)
in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk
regions of Latin America.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
Cancer Prevention Pharmaceuticals, Inc. National Cancer Institute (NCI)